A recent vote by an FDA advisory committee is recommending eventual FDA approval of Palforzia, a novel therapy that may be indicated for patients between 4 and 17 years with peanut allergies.
Previous studies have shown that 67.2% of patients between ages 4 and 17 years old were able to ingest a dose of 600 mg or more of peanut protein after receiving Palforzia compared to 4% of patients who received the placebo. This effect was not seen in patients 18 years or older.
This therapy is not a cure for peanut allergy but may prevent severe allergic reactions from accidental ingestion of peanuts.
An anticipated date for final approval by the FDA may be in late January 2020.